placeholder image
M. Najdowski All authors
About
Publications While At HealthPartners
Highlights
selected publications
Journal Article
  • Effectiveness of nirsevimab among infants in their first RSV season in the United States, October 2023-March 2024: a test-negative design analysis. 
    Lancet Reg Health Am. 2025
  • Estimated 2023-2024 COVID-19 vaccine effectiveness in adults. 
    JAMA network open. 2025
  • Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 
    Lancet (London, England). 2024
  • Risk of COVID-19 hospitalization and protection associated with mRNA vaccination among US adults with psychiatric disorders. 
    Influenza and other respiratory viruses. 2024
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 
    American Journal of Transplantation. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 
    MMWR: Morbidity and Mortality Weekly Report. 2023
    • Contact
    full name
  • M. Najdowski
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
    Collaboration